Digital Content 
NEWS #PharmaBuzz
18 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2025/03/19/3045072/0/en/HUTCHMED-and-Innovent-Jointly-Announce-that-the-FRUSICA-2-Phase-II-III-Study-of-Fruquintinib-and-Sintilimab-Combination-Has-Met-its-Primary-Endpoint-in-Advanced-Renal-Cell-Carcinom.html
18 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/innovent-and-hutchmed-jointly-announce-that-the-frusica-2-phase-23-study-of-sintilimab-and-fruquintinib-combination-has-met-its-primary-endpoint-in-advanced-renal-cell-carcinoma-in-china-302405211.html
03 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/03/2990362/0/en/HUTCHMED-and-Innovent-Jointly-Announce-NMPA-Conditional-Approval-for-ELUNATE-Fruquintinib-in-Combination-with-TYVYT-Sintilimab-Injection-for-the-Treatment-of-Advanced-Endometrial-C.html
02 Jun 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/innovent-delivers-oral-presentation-of-clinical-data-of-a-randomized-controlled-phase-1b-study-evaluating-ibi310-anti-ctla-4-monoclonal-antibody-in-combination-with-sintilimab-as-neoadjuvant-treatment-of-colon-cancer-at-2024-asc-302161380.html
01 Apr 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/04/02/2855618/0/en/HUTCHMED-and-Innovent-Jointly-Announce-NDA-Acceptance-in-China-for-Fruquintinib-Combination-with-Sintilimab-for-the-Treatment-of-Advanced-Endometrial-Cancer-with-Priority-Review-St.html
26 Mar 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/innovent-dosed-first-participant-in-phase-3-clinical-study-neoshot-of-ibi310-anti-ctla-4-monoclonal-antibody-in-combination-with-sintilimab-for-msi-hdmmr-colon-cancer-neoadjuvant-therapy-302099295.html
Share 